Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
As of today, Moderna(MRNA) shares are valued at $44.13. The company's market cap stands at 17.16B, with a P/E ratio of -6.05.
On 2026-02-18, Moderna(MRNA) stock traded between a low of $41.97 and a high of $45.07. Shares are currently priced at $44.13, which is +5.1% above the low and -2.1% below the high.
Moderna(MRNA) shares are trading with a volume of 10.45M, against a daily average of 10.48M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
MRNA News
RBC Capital analyst Luca Issi raised the firm’s price target on Moderna (MRNA) to $30 from $25 and keeps a Sector Perform rating on the shares. The company’s Q4...
Evercore ISI analyst Cory Kasimov raised the firm’s price target on Moderna (MRNA) to $35 from $28 and keeps an In Line rating on the shares. The firm updated i...
Shares of Moderna, Inc. MRNA rose 5.3% on Friday, Feb. 13, as investors showed renewed interest in large-cap biotech names. The gain stood out against a choppy...
Analyst ratings
70%
of 27 ratingsMore MRNA News
FDA declined to review Moderna’s mRNA flu vaccine application, despite prior agreement on study design. The decision reportedly went against the recommendation...
Moderna ((MRNA)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-level data and pow...
Moderna Inc. (NASDAQ:MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago. The COV...
Image source: The Motley Fool. Feb. 13, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Stéphane Bancel President — Stephen Hoge Chief Financ...
Technology Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks? Licensing Moderna (MRNA) stock popped Friday after the company report...
(RTTNews) - Moderna, Inc. (MRNA), a biotechnology company, Friday reported narrower loss for the fourth quarter compared to the same period last year. Quarterl...
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way Quick Read Moderna (MRNA) beat Q4 expectations with $678M revenue but total sales fell...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.